BIND Therapeutics, Inc.

BIND Biosciences, Inc. Closes $11M Series C Financing Round

BIND Biosciences, Inc. Closes $11M Series C Financing Round

January 14, 2010

High-Precision Therapeutics through Medicinal Nanoengineering™

VisEn Medical, Inc.

VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent

VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent

January 19, 2010

Extends VisEn’s Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Expanded Readouts of Key Protease Biomarkers in Research and Drug Development

BEDFORD, MA (January 19, 2010)—VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

Helicos BioSciences Corporation

Helicos BioSciences Announces the Sale of a Helicos® Genetic Analysis System to the Turku Centre for Biotechnology

Helicos BioSciences Announces the Sale of a Helicos® Genetic Analysis System to the Turku Centre for Biotechnology

January 19, 2010

CAMBRIDGE, Mass., Jan 19, 2010 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS), today announced the sale of a Helicos® Genetic Analysis System to the Turku Centre for Biotechnology in Turku, Finland. The center, led by Dr. Riitta Lahesmaa, is a joint facility of the University of Turku and Åbo Akademi University.

"We are very excited by our acquisition of a Helicos System, as it will allow us to perform novel experiments using single molecule sequencing technology." said Riitta Lahesmaa, Director of the center.

Joule Unlimited, Inc.

Joule Biotechnologies Secures Pilot Site for Renewable Solar Fuel

Joule Biotechnologies Secures Pilot Site for Renewable Solar Fuel

January 20, 2010

CAMBRIDGE, Mass.--Joule Biotechnologies, Inc. today announced the signing of a lease agreement to build its first pilot plant in Leander, Texas, where the company will further develop and test its transformative system for the production of renewable solar fuels. Powered by sunlight and free of costly feedstocks or processing steps, the system is being engineered to eclipse the productivities, scale and cost efficiencies of biomass-dependent approaches. The site was chosen in part for its high solar insolation and logistically convenient location.

Novomer, Inc.

DSM and Novomer to Develop First CO2-based Resin for Coatings

DSM and Novomer to Develop First CO2-based Resin for Coatings

January 21, 2010

HEERLEN, THE NETHERLANDS -- (MARKET WIRE) -- 01/21/10 -- Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and Novomer Inc., based in Waltham (Massachusetts, United States), today announce that they have signed an agreement to jointly develop a revolutionary coating resin using carbon dioxide (CO2) as a raw material.

LS9

LS9, Inc., U.C Berkeley, and JBEI Make Major Breakthrough in Cellulosic Fuels Production

LS9, Inc., U.C Berkeley, and JBEI Make Major Breakthrough in Cellulosic Fuels Production

January 27, 2010

Researchers Develop Microbes that Produce Fuels Directly from Cellulosic Biomass

South San Francisco, CA (PRWEB) January 27, 2010 -- LS9, Inc, the Renewable Petroleum Company™, today announced a major breakthrough in the ability to make cellulosic-derived advanced biofuels. A collaborative team of researchers from LS9, Inc, the University of California at Berkeley, and the U.S. Department of Energy’s Joint BioEnergy Institute (JBEI) have developed a microbe that can produce an advanced biofuel directly from cellulosic biomass in a one-step process.

BG Medicine, Inc.

BG Medicine Announces Receipt of CE Mark for its Galectin-3 Blood Test 01/27/2010

BG Medicine Announces Receipt of CE Mark for its Galectin-3 Blood Test 01/27/2010

January 27, 2010

BG Medicine Initiates Commercialization in the European Union

Waltham, MA, USA—January 27, 2010—BG Medicine, Inc., a privately-held developer of biomarker-based in vitro diagnostics, today announced the commercial launch in the European Union of a new, CE-marked test for the measurement of galectin-3 in human plasma or serum. Galectin-3 was first shown by researchers at the University of Maastricht, The Netherlands, to play an integral role in the development and progression of heart failure.

Joule Unlimited, Inc.

Joule Names Troy Campione Senior Vice President of Corporate Development

Joule Names Troy Campione Senior Vice President of Corporate Development

January 27, 2010

Cambridge, Mass. – January 27, 2010 – Joule today announced the appointment of Dr. Troy J. Campione as Senior Vice President of Corporate Development. In this newly-created role he will lead Joule’s business development strategy and execution, including the negotiation of partnership and development agreements across multiple market segments.

VisEn Medical, Inc.

VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms from Bayer Schering Pharma

VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms from Bayer Schering Pharma

January 28, 2010

Consolidates the Leading Intellectual Property Positions and Technologies In Fluorescence In Vivo Imaging Agents

BG Medicine, Inc.

BG Medicine Files Registration Statement for Proposed Initial Public Offering

BG Medicine Files Registration Statement for Proposed Initial Public Offering

January 29, 2010

Waltham, MA - January 29, 2010 - BG Medicine, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range of the offering have not yet been determined.